|
US5624898A
(en)
|
1989-12-05 |
1997-04-29 |
Ramsey Foundation |
Method for administering neurologic agents to the brain
|
|
US6407061B1
(en)
|
1989-12-05 |
2002-06-18 |
Chiron Corporation |
Method for administering insulin-like growth factor to the brain
|
|
ATE156704T1
(de)
|
1989-12-05 |
1997-08-15 |
Ramsey Foundation |
Neurologische wirkstoffe zur nasalen verabreichung an das gehirn
|
|
KR930703447A
(ko)
|
1991-11-14 |
1993-11-30 |
지오프리 태터살 |
합성 알파-엘-이두로니다제 및 이를 암호화하는 유전자 서열
|
|
FR2716893B1
(fr)
|
1994-03-03 |
1996-04-12 |
Rhone Poulenc Rorer Sa |
Virus recombinants, leur préparation et leur utilisation thérapeutique.
|
|
US6190659B1
(en)
|
1996-09-17 |
2001-02-20 |
The Rockefeller University |
Bacterial plasmin binding protein and methods of use thereof
|
|
AU8672198A
(en)
|
1997-07-31 |
1999-02-22 |
Chiron Corporation |
Method enabling readministration of aav vector via immunosuppression of host
|
|
ES2326893T3
(es)
|
1998-05-27 |
2009-10-21 |
Genzyme Corporation |
Vectores aav para la fabricacion de medicamentos para administracion potenciada por conveccion.
|
|
JP2002531489A
(ja)
|
1998-12-09 |
2002-09-24 |
カイロン コーポレイション |
中枢神経系への神経栄養剤の投与
|
|
US7273618B2
(en)
|
1998-12-09 |
2007-09-25 |
Chiron Corporation |
Method for administering agents to the central nervous system
|
|
JP2002531490A
(ja)
|
1998-12-09 |
2002-09-24 |
カイロン コーポレイション |
中枢神経系に薬剤を投与するための方法
|
|
DE60039766D1
(de)
|
1999-08-09 |
2008-09-18 |
Targeted Genetics Corp |
Terologen nukleotidsequenz von einem rekombinanten viralen vektor durch ausgestaltung der sequenz in einer art und weise, dass basenpaarungen innerhalb der sequenz entstehen
|
|
US6426208B1
(en)
|
1999-11-12 |
2002-07-30 |
Harbor-Ucla Research And Education Institute |
Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
|
|
US6585971B1
(en)
|
1999-11-12 |
2003-07-01 |
Harbor-Ucla Research And Education Institute |
Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating disease caused by deficiencies thereof
|
|
US6569661B1
(en)
|
1999-11-12 |
2003-05-27 |
Biomarin Pharmaceutical Inc. |
Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
|
|
US6582692B1
(en)
|
1999-11-17 |
2003-06-24 |
Avigen, Inc. |
Recombinant adeno-associated virus virions for the treatment of lysosomal disorders
|
|
DE60021760T2
(de)
|
1999-12-09 |
2006-06-08 |
Chiron Corp., Emeryville |
Verfahren zur verabreichung von wirkstoffen in das zentrale nervensystem oder lymphsystem
|
|
US7084126B1
(en)
|
2000-05-01 |
2006-08-01 |
Healthpartners Research Foundation |
Methods and compositions for enhancing cellular function through protection of tissue components
|
|
US20040204379A1
(en)
|
2000-06-19 |
2004-10-14 |
Cheng Seng H. |
Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
|
|
WO2002002597A2
(en)
|
2000-06-30 |
2002-01-10 |
Maxygen Aps |
Peptide extended glycosylated polypeptides
|
|
ES2799882T3
(es)
|
2000-07-18 |
2020-12-22 |
Univ Duke |
Tratamiento de glucogenosis de tipo II
|
|
US20020014242A1
(en)
|
2000-07-31 |
2002-02-07 |
Abraham Scaria |
Use of rapamycin to inhibit immune response and induce tolerance to gene therapy vector and encoded transgene products
|
|
AU2002211688A1
(en)
|
2000-10-13 |
2002-04-29 |
Chiron Corporation |
Method for treating ischemic events affecting the central nervous system
|
|
US20020169102A1
(en)
|
2001-04-03 |
2002-11-14 |
Frey William H. |
Intranasal delivery of agents for regulating development of implanted cells in the CNS
|
|
JP2004532849A
(ja)
|
2001-04-20 |
2004-10-28 |
カイロン コーポレイション |
中枢神経系へのポリヌクレオチド薬剤の送達
|
|
CA2915124C
(en)
|
2001-11-13 |
2018-08-14 |
The Trustees Of The University Of Pennsylvania |
A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
|
|
ES2602352T3
(es)
|
2001-12-17 |
2017-02-20 |
The Trustees Of The University Of Pennsylvania |
Secuencias de serotipo 8 de virus adenoasociado (VAA), vectores que las contienen y usos de las mismas
|
|
JP2005524649A
(ja)
|
2002-02-25 |
2005-08-18 |
カイロン コーポレーション |
Ｍｃ４−ｒアゴニストの鼻腔内投与
|
|
AU2004226961B2
(en)
|
2002-05-01 |
2009-06-11 |
University Of Florida Research Foundation, Inc. |
VP2-modified rAAV vector compositions and uses therefor
|
|
US7485314B2
(en)
|
2002-05-06 |
2009-02-03 |
Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center |
Induction of antigen specific immunologic tolerance
|
|
WO2004055157A2
(en)
|
2002-08-13 |
2004-07-01 |
Whitley Chester B |
Methods of using vectors to treat metabolic disorders
|
|
US7666843B2
(en)
|
2002-09-27 |
2010-02-23 |
Children's Medical Center Corporation |
Methods and compositions for treatment of neurological disorder
|
|
US8512710B2
(en)
|
2002-11-22 |
2013-08-20 |
Ansun Biopharma, Inc. |
Class of therapeutic protein based molecules
|
|
US7446098B2
(en)
|
2003-02-18 |
2008-11-04 |
Mount Sinai School Of Medicine Of New York University |
Combination therapy for treating protein deficiencies
|
|
US20050026823A1
(en)
|
2003-06-20 |
2005-02-03 |
Biomarin Pharmaceutical Inc. |
Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
|
|
US7442372B2
(en)
|
2003-08-29 |
2008-10-28 |
Biomarin Pharmaceutical Inc. |
Delivery of therapeutic compounds to the brain and other tissues
|
|
EP2298926A1
(en)
|
2003-09-30 |
2011-03-23 |
The Trustees of The University of Pennsylvania |
Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses thereof
|
|
WO2005062881A2
(en)
|
2003-12-24 |
2005-07-14 |
Transgenrx, Inc. |
Gene therapy using transposon-based vectors
|
|
US7776312B2
(en)
|
2004-08-13 |
2010-08-17 |
Healthpartners Research Foundation |
Method of treating Alzheimer's disease comprising administering deferoxamine (DFO) to the upper one-third of the nasal cavity
|
|
US7618615B2
(en)
|
2004-08-13 |
2009-11-17 |
Healthpartners Research Foundation |
Methods for providing neuroprotection for the animal central nervous system against neurodegeneration caused by ischemia
|
|
WO2006091332A2
(en)
|
2005-02-23 |
2006-08-31 |
Alza Corporation |
Intranasal administration of active agents to the central nervous system
|
|
US20090136505A1
(en)
|
2005-02-23 |
2009-05-28 |
Johanna Bentz |
Intranasal Administration of Active Agents to the Central Nervous System
|
|
EP2357010B1
(en)
|
2005-04-07 |
2013-06-12 |
The Trustees of The University of Pennsylvania |
Method of increasing the function of an AAV vector
|
|
US7456683B2
(en)
|
2005-06-09 |
2008-11-25 |
Panasonic Corporation |
Amplitude error compensating device and quadrature skew error compensating device
|
|
EP1928484B1
(en)
|
2005-08-26 |
2010-02-24 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods for treatment of headaches by administration of oxytocin
|
|
AR059371A1
(es)
|
2006-02-08 |
2008-03-26 |
Genzyme Corp |
Terapia genica para la enfermedad de niemann-pick tipo a
|
|
CA2641359C
(en)
|
2006-02-09 |
2022-10-04 |
Genzyme Corporation |
Slow intraventricular delivery
|
|
EP2007795B1
(en)
|
2006-03-30 |
2016-11-16 |
The Board Of Trustees Of The Leland Stanford Junior University |
Aav capsid proteins
|
|
US8153604B2
(en)
|
2006-04-24 |
2012-04-10 |
Geron Corporation |
CNS-tumor treatment method and composition
|
|
EP1915986A1
(en)
|
2006-10-23 |
2008-04-30 |
BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG VON PHARMAKA mbH |
Lipid growth factor formulations
|
|
EP2132309A4
(en)
|
2007-02-23 |
2011-01-05 |
Univ Florida |
COMPOSITIONS AND METHODS OF TREATING GLYCOLOGICAL MEMORY DISEASES
|
|
US20120322861A1
(en)
|
2007-02-23 |
2012-12-20 |
Barry John Byrne |
Compositions and Methods for Treating Diseases
|
|
PT3252161T
(pt)
|
2007-06-06 |
2022-02-01 |
Genzyme Corp |
Terapia genética para doenças do armazenamento lisossomal
|
|
US9808509B2
(en)
|
2007-06-08 |
2017-11-07 |
Healthpartners Research Foundation |
Pharmaceutical compositions and methods for enhancing targeting of therapeutic compounds to the central nervous system
|
|
US8283160B2
(en)
|
2007-09-11 |
2012-10-09 |
Frey Ii William H |
Methods, pharmaceutical compositions and articles of manufacture for administering therapeutic cells to the animal central nervous system
|
|
EP2058401A1
(en)
|
2007-10-05 |
2009-05-13 |
Genethon |
Widespread gene delivery to motor neurons using peripheral injection of AAV vectors
|
|
WO2009075815A1
(en)
|
2007-12-07 |
2009-06-18 |
Duke University |
Immunomodulating gene therapy
|
|
WO2009097129A1
(en)
|
2008-01-29 |
2009-08-06 |
Applied Genetic Technologies Corporation |
Recombinant virus production using mammalian cells in suspension
|
|
US9265843B2
(en)
|
2008-03-27 |
2016-02-23 |
The Ohio State University |
Treatment of metabolic-related disorders using hypothalamic gene transfer of BDNF and compositions therefor
|
|
US8632764B2
(en)
|
2008-04-30 |
2014-01-21 |
University Of North Carolina At Chapel Hill |
Directed evolution and in vivo panning of virus vectors
|
|
US11219696B2
(en)
|
2008-12-19 |
2022-01-11 |
Nationwide Children's Hospital |
Delivery of polynucleotides using recombinant AAV9
|
|
US9415121B2
(en)
|
2008-12-19 |
2016-08-16 |
Nationwide Children's Hospital |
Delivery of MECP2 polynucleotide using recombinant AAV9
|
|
WO2010071832A1
(en)
|
2008-12-19 |
2010-06-24 |
Nationwide Children's Hospital |
Delivery of polynucleotides across the blood brain barrier using recombinant aav9
|
|
US7989502B2
(en)
|
2009-02-06 |
2011-08-02 |
Sri International |
Intranasal delivery of modafinil
|
|
ES2634118T3
(es)
|
2009-02-11 |
2017-09-26 |
The University Of North Carolina At Chapel Hill |
Vectores de virus modificados y métodos para fabricar y utilizar los mismos
|
|
US8734809B2
(en)
|
2009-05-28 |
2014-05-27 |
University Of Massachusetts |
AAV's and uses thereof
|
|
US20110070241A1
(en)
|
2009-06-30 |
2011-03-24 |
Duke University |
Methods for modulating immune responses to aav gene therapy vectors
|
|
US8622993B2
(en)
|
2009-12-18 |
2014-01-07 |
Healthpartners Research Foundation |
Device and method for delivering therapeutic substances to the maxillary sinus of a patient
|
|
KR20150135552A
(ko)
*
|
2010-03-03 |
2015-12-02 |
테바 파마슈티컬 인더스트리즈 리미티드 |
라퀴니모드를 이용한 루푸스 신장염의 치료
|
|
SG10201502270TA
(en)
|
2010-03-29 |
2015-05-28 |
Univ Pennsylvania |
Pharmacologically induced transgene ablation system
|
|
EP3514232A1
(en)
|
2010-04-23 |
2019-07-24 |
University of Massachusetts |
Cns targeting aav vectors and methods of use thereof
|
|
US8927514B2
(en)
|
2010-04-30 |
2015-01-06 |
City Of Hope |
Recombinant adeno-associated vectors for targeted treatment
|
|
EP2394667A1
(en)
|
2010-06-10 |
2011-12-14 |
Laboratorios Del Dr. Esteve, S.A. |
Vectors and sequences for the treatment of diseases
|
|
DK2588130T3
(en)
|
2010-06-25 |
2016-10-24 |
Shire Human Genetic Therapies |
Cns delivery of therapeutic agents
|
|
HRP20191924T1
(hr)
|
2010-06-25 |
2020-01-10 |
Shire Human Genetic Therapies, Inc. |
Postupci i sastavi za isporuku iduronat-2-sulfataze u cns
|
|
MX2013000320A
(es)
|
2010-06-25 |
2013-06-05 |
Shire Human Genetic Therapies |
Composiciones y metodos para suministro al sistema nervioso central de heparan n-sulfatasa.
|
|
NZ605873A
(en)
|
2010-06-25 |
2015-02-27 |
Shire Human Genetic Therapies |
Methods and compositions for cns delivery of arylsulfatase a
|
|
PT3626258T
(pt)
|
2010-06-25 |
2021-10-19 |
Shire Human Genetic Therapies |
Métodos e composições para fornecimento ao snc de iduronato-2-sulfatase
|
|
WO2012101671A1
(en)
|
2011-01-25 |
2012-08-02 |
Jcr Pharmaceuticals Co., Ltd. |
Method for production of human recombinant iduronate 2-sulfatase
|
|
EP4234571A3
(en)
|
2011-02-10 |
2023-09-27 |
The University of North Carolina at Chapel Hill |
Viral vectors with modified transduction profiles and methods of making and using the same
|
|
JP6224459B2
(ja)
|
2011-02-17 |
2017-11-01 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
組織特異性を改変し、ａａｖ９媒介遺伝子導入を改善するための組成物および方法
|
|
WO2012135857A1
(en)
|
2011-03-31 |
2012-10-04 |
University Of Iowa Research Foundation |
Methods and compositions for treating brain diseases
|
|
US10196636B2
(en)
|
2011-04-21 |
2019-02-05 |
Nationwide Children's Hospital, Inc. |
Recombinant virus products and methods for inhibition of expression of myotilin
|
|
EP2699673B1
(en)
|
2011-04-21 |
2018-09-19 |
Nationwide Children's Hospital, Inc. |
Recombinant virus products and methods for inhibition of expression of myotilin
|
|
US8609088B2
(en)
|
2011-05-10 |
2013-12-17 |
Regents Of The University Of Minnesota |
Intranasal delivery of therapeutic enzymes to the central nervous system for the treatment of lysosomal storage diseases
|
|
US10227387B2
(en)
|
2011-05-18 |
2019-03-12 |
Children's Hospital Medical Center |
Targeted delivery of proteins across the blood-brain barrier
|
|
US20130039888A1
(en)
|
2011-06-08 |
2013-02-14 |
Nationwide Children's Hospital Inc. |
Products and methods for delivery of polynucleotides by adeno-associated virus for lysosomal storage disorders
|
|
US9387236B2
(en)
|
2011-06-10 |
2016-07-12 |
Prothera Inc. |
Pharmaceutical compositions containing protease and methods for the treatment of lysosomal storage diseases
|
|
ES2990023T3
(es)
|
2011-07-25 |
2024-11-28 |
Nationwide Childrens Hospital Inc |
Productos de virus recombinantes y métodos para inhibición de la expresión de DUX4
|
|
JP6329483B2
(ja)
|
2011-10-12 |
2018-05-23 |
シナジェバ・バイオファーマ・コーポレイションＳｙｎａｇｅｖａ Ｂｉｏｐｈａｒｍａ Ｃｏｒｐ． |
組換えヒトｎａｇｌｕタンパク質およびその利用
|
|
US9821149B2
(en)
|
2011-10-14 |
2017-11-21 |
Healthpartners Research & Education |
Methods for using ultrasound for enhancing efficiency and targeting of intranasal administration of therapeutic compounds to the central nervous system
|
|
CA2852955C
(en)
|
2011-10-27 |
2021-02-16 |
Sangamo Biosciences, Inc. |
Methods and compositions for modification of the hprt locus
|
|
ES2983576T3
(es)
|
2011-12-02 |
2024-10-23 |
Armagen Inc |
Métodos y composiciones para aumentar la actividad arilsulfatasa en el SNC
|
|
CN107982548A
(zh)
|
2012-02-07 |
2018-05-04 |
全球生物疗法有限公司 |
核酸输送的区室化方法及其组合物和应用
|
|
WO2013141119A1
(ja)
|
2012-03-23 |
2013-09-26 |
テルモ株式会社 |
穿刺器具および穿刺装置
|
|
EP4124346A3
(en)
|
2012-06-19 |
2023-04-19 |
University of Florida Research Foundation, Inc. |
Compositions and methods for treating diseases
|
|
CN104704123A
(zh)
|
2012-06-21 |
2015-06-10 |
肌肉学研究协会 |
基因治疗载体的广泛的基因递送
|
|
EP3769789A1
(en)
|
2012-08-01 |
2021-01-27 |
Nationwide Children's Hospital |
Intrathecal delivery of recombinant adeno-associated virus 9
|
|
US12024568B2
(en)
|
2012-09-13 |
2024-07-02 |
Cornell University |
Treatment of brain cancers using central nervous system mediated gene transfer of monoclonal antibodies
|
|
RU2680581C2
(ru)
|
2012-11-27 |
2019-02-22 |
Байомарин Фармасьютикал Инк. |
Направленные терапевтические химерные белки лизосомальных ферментов и их применение
|
|
WO2014125647A1
(ja)
|
2013-02-18 |
2014-08-21 |
富士通オプティカルコンポーネンツ株式会社 |
光受信装置
|
|
EP3747998B1
(en)
|
2013-03-15 |
2024-07-24 |
The Trustees of the University of Pennsylvania |
Compositions for treating mpsi
|
|
MX388221B
(es)
|
2013-04-20 |
2025-03-19 |
Res Institute At Nationwide Children´S Hospital |
ADMINISTRACIÓN DE VIRUS ADENO-ASOCIADO RECOMBINANTE DE CONSTRUCCIONES DE POLINUCLÉOTIDOS U7snRNA DIRIGIDA AL EXÓN 2.
|
|
AU2013388083B2
(en)
|
2013-05-01 |
2019-08-22 |
Genzyme Corporation |
Compositions and methods for treating spinal muscular atrophy
|
|
RU2692251C2
(ru)
|
2013-05-15 |
2019-06-24 |
Риджентс Оф Зэ Юниверсити Оф Миннесота |
Опосредованный аденоассоциированным вирусом перенос генов в центральную нервную систему
|
|
MX373332B
(es)
|
2013-07-26 |
2020-05-21 |
Univ Iowa Res Found |
UNA PARTÍCULA rAAV Y UN AGENTE DE INMUNOSUPRESIÓN PARA USARSE EN EL TRATAMIENTO DE ENFERMEDADES.
|
|
US11364032B2
(en)
|
2013-08-08 |
2022-06-21 |
Global Bio Therapeutics, Inc. |
Clamp device for minimally invasive procedures and uses thereof
|
|
PL3702466T3
(pl)
|
2013-08-27 |
2023-04-24 |
Research Institute At Nationwide Children's Hospital |
Produkty i sposoby do leczenia stwardnienia zanikowego bocznego
|
|
US9585971B2
(en)
|
2013-09-13 |
2017-03-07 |
California Institute Of Technology |
Recombinant AAV capsid protein
|
|
CA2927366A1
(en)
|
2013-10-24 |
2015-04-30 |
Uniqure Ip B.V. |
Aav-5 pseudotyped vector for gene therapy for neurological diseases
|
|
US20170049887A1
(en)
|
2014-04-25 |
2017-02-23 |
University Of Florida Research Foundation, Inc. |
Methods of permitting a subject to receive multiple doses of recombinant adeno-associated virus
|
|
US10053671B2
(en)
|
2014-06-20 |
2018-08-21 |
Wisconsin Alumni Research Foundation (Warf) |
Mutations that confer genetic stability to additional genes in influenza viruses
|
|
EP3800260A1
(en)
|
2014-09-24 |
2021-04-07 |
City of Hope |
Adeno-associated virus vector variants for high efficiency genome editing and methods thereof
|
|
US10370432B2
(en)
|
2014-10-03 |
2019-08-06 |
University Of Massachusetts |
Heterologous targeting peptide grafted AAVS
|
|
JP6754361B2
(ja)
*
|
2014-12-16 |
2020-09-09 |
ボード オブ リージェンツ オブ ザ ユニバーシティ オブ ネブラスカ |
若年型バッテン病のための遺伝子療法
|
|
US10538589B2
(en)
|
2015-01-14 |
2020-01-21 |
Armagen Inc. |
Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU
|
|
WO2016187017A1
(en)
|
2015-05-15 |
2016-11-24 |
Mcivor R Scott |
Adeno-associated for therapeutic delivery to central nervous system
|
|
EP3101125A1
(en)
|
2015-06-05 |
2016-12-07 |
Laboratorios Del Dr. Esteve, S.A. |
Adenoassociated virus vectors for the treatment of mucopolysaccharidoses
|
|
WO2017011519A1
(en)
|
2015-07-13 |
2017-01-19 |
Sangamo Biosciences, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering
|
|
GB2557123B
(en)
|
2015-07-31 |
2021-11-03 |
Univ Minnesota |
Modified cells and methods of therapy
|
|
WO2017075119A1
(en)
*
|
2015-10-28 |
2017-05-04 |
The Trustees Of The Univeresity Of Pennsylvania |
Intrathecal administration of adeno-associated-viral vectors for gene therapy
|
|
EP3402533B1
(en)
|
2016-01-15 |
2021-08-04 |
Sangamo Therapeutics, Inc. |
Methods and compositions for the treatment of neurologic disease
|
|
US10973929B2
(en)
|
2016-02-03 |
2021-04-13 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating mucopolysaccharidosis type I
|
|
IL300254B2
(en)
|
2016-02-05 |
2025-06-01 |
Univ Emory |
Administration of single stranded or self-complementary adeno-associated virus 9 by injection into the cerebrospinal fluid to target gene therapy to the central nervous system
|
|
US10561894B2
(en)
|
2016-03-18 |
2020-02-18 |
Icon Health & Fitness, Inc. |
Treadmill with removable supports
|
|
WO2017181113A1
(en)
*
|
2016-04-15 |
2017-10-19 |
The Trustees Of The University Of Pennsyvania |
Gene therapy for treating mucopolysaccharidosis type ii
|
|
KR20190086503A
(ko)
|
2016-11-15 |
2019-07-22 |
리젠츠 오브 더 유니버시티 오브 미네소타 |
Mpsi 및 mpsii에서의 신경계 기능 및 다른 신경계 장애를 개선하는 방법
|
|
UY37587A
(es)
|
2017-01-31 |
2018-08-31 |
Regenxbio Inc |
Tratamiento de mucopolisacaridosis i con alfa-l-iduronidasa (idua) humana glicosilada completamente humana
|
|
RU2019139555A
(ru)
|
2017-05-11 |
2021-06-11 |
Зе Трастис Оф Зе Юниверсити Оф Пеннсильвания |
Генная терапия нейрональных цероидных липофусцинозов
|
|
JP2020526514A
(ja)
|
2017-07-06 |
2020-08-31 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
ムコ多糖症ｉ型を治療するための遺伝子治療
|
|
TWI835747B
(zh)
*
|
2017-09-22 |
2024-03-21 |
賓州大學委員會 |
用於治療黏多醣病 ii 型之基因治療
|
|
IL280198B1
(en)
|
2018-07-18 |
2025-09-01 |
Regenxbio Inc |
Treatment of mucopolysaccharidosis I with fully glycosylated human iduronidase-alpha-L (idus)
|
|
WO2021070082A1
(en)
|
2019-10-07 |
2021-04-15 |
Wӓrtsilӓ Services Switzerland Ltd. |
Step lift control of hydraulically actuated poppet valves
|
|
JP2023511382A
(ja)
|
2020-01-22 |
2023-03-17 |
レジェンクスバイオ インコーポレーテッド |
完全ヒトグリコシル化ヒトα－Ｌ－イズロニダーゼ（ＩＤＵＡ）を用いたムコ多糖症Ｉ型の治療
|